Biofrontera (BFRI) EBITDA (2020 - 2025)

Biofrontera's EBITDA history runs 6 years deep, the most recent figure standing at $4.6 million for Q4 2025.

• In Q4 2025, EBITDA rose 366.3% year-over-year to $4.6 million; the TTM figure through Dec 2025 stood at -$11.3 million (up 34.08% YoY), while the FY2025 annual figure was -$11.3 million, up 34.06% from the prior year.
• EBITDA was $4.6 million for Q4 2025 at Biofrontera, up from -$6.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $4.6 million in Q4 2025 to a low of -$16.1 million in Q3 2021.
• Historically, EBITDA has averaged -$4.7 million across 5 years, with a median of -$4.8 million in 2023.
• The sharpest annual moves came in 2021 and 2025: EBITDA tumbled 911.17% in 2021, then jumped 366.3% in 2025.
• A 5-year view of EBITDA shows it stood at -$1.9 million in 2021, then plunged by 193.58% to -$5.6 million in 2022, then jumped by 30.75% to -$3.9 million in 2023, then surged by 55.71% to -$1.7 million in 2024, then surged by 366.3% to $4.6 million in 2025.
• The last three EBITDA figures came in at $4.6 million (Q4 2025), -$6.3 million (Q3 2025), and -$5.1 million (Q2 2025), per Business Quant data.